Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema
NCT04687137
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Hereditary Angioedema
Interventions
DRUG:
TAK-743 300 mg
Sponsor
Takeda